Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 25:ciaf079.
doi: 10.1093/cid/ciaf079. Online ahead of print.

Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease

Tessa Adzemovic  1 , Elizabeth Nalintya  1 , Ann Fieberg  2 , Emmanuel Mande  1 , Katende George  1 , Spencer Yueh  1 , Olive Namakula  1 , Patricia Nerima  1 , Biyue Dai  2 , David B Meya  1   3 , David R Boulware  2 , Radha Rajasingham  2
Affiliations

Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease

Tessa Adzemovic et al. Clin Infect Dis. .

Abstract

Background: An urgent need exists for point-of-care diagnostics to detect tuberculosis (TB) among people with advanced human immunodeficiency virus (HIV) disease. The Fujifilm SILVAMP TB LAM (FujiLAM II) is a novel point-of-care assay that detects mycobacterial lipoarabinomannan (LAM) antigen in the urine to identify TB. We present a validation of the FujiLAM II assay on prospectively collected urine samples from outpatient adults with advanced HIV disease in Uganda.

Methods: We performed a prospective diagnostic accuracy study of the FujiLAM II assay among outpatients with advanced HIV disease at 16 clinics Uganda. FujiLAM II was run on cryopreserved urine. We determined diagnostic performance for the FujiLAM II test against the cases of confirmed TB (Xpert or mycobacterial culture positive) versus cases without TB. We additionally assessed sensitivity and specificity of the FujiLAM II assay as compared with confirmed TB among pre-specified subgroups: CD4 <100 cells/µL versus 100-200 cells/µL, antiretroviral therapy (ART) naive versus experienced, and CRP <5 mg/L versus ≥5 mg/L.

Results: Among 583 participants who had FujiLAM II testing performed, the FujiLAM II assay demonstrated 54% (25/46) (95% confidence interval [CI]: 40%-69%) sensitivity to identify confirmed TB and 95% (326/342) (95% CI: 93% to 98%) specificity to identify the absence of TB. Among participants with CD4 cell counts <100 cells/µL, FujiLAM II sensitivity was 69% (95% CI: 53%-85%) and specificity was 94% (95% CI: 90%-97%). Among participants with serum C-reactive protein (CRP) ≥5 mg/L, the FujiLAM II assay exhibited a sensitivity of 62% (95% CI: 46%-77%) and specificity of 93% (95% CI: 89%-98%).

Conclusions: FujiLAM II is a point-of-care, non-sputum based TB diagnostic with moderate sensitivity and high specificity in outpatients with advanced HIV disease.

Keywords: FujiLAM; Liparabinomannan (LAM); advanced HIV; diagnostics; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.